From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver Pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and business process infrastructure for market access and therapy commercialization.
Solutions overview
IntegriChain delivers the life science industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, managed services and expert advisors to power their operations and harness the value of their channel, patient and payer data.
View all products
To ensure you get the most out of your access and commercialization investment, IntegriChain provides a complete set of professional Advisory and Systems Integration Services designed to further your business and success.
Services overview
IntegriChain provides wide array of resources to help you navigate your journey to market access success.
Resources overview
We help all stakeholders in the life sciences industry drive access. We do this through our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts and pricing, gross-to-net, channel, and patient services – unlocking strategic payer, provider, pharmacy and patient access insights for our life sciences customers.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, Market Access experts, analysts, technologies, and advisory professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
A top-10 pharmaceutical manufacturer had not refreshed their distribution services agreement (DSA) in over a decade. As a result, their distribution model relied on outdated modes of control, did not support the site of care landed product cost and it was not well-positioned to support the future portfolio, consisting mainly of specialty and orphan drug brands. Initial discussions with the client’s distribution accounts were leading the client team to believe they would have to spend $50M – $100M in additional fees and discounts to support their current distribution model over a 3-year contract term. After meeting with Blue Fin Group, they realized that wasn’t the case. Download the case study to find out more
Download now!